GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

British pharmaceutical company GSK on Wednesday said it swung into a ... to offset lower vaccine sales and reflected successful new product launches in oncology and HIV," chief executive Emma ...

Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK's severe asthma therapy Nucala could ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK ...

The Federal Government is advancing its commitment to ensure a self-sustaining healthcare system by collaborating with ...